Livedoid vasculopathy and high levels of lipoprotein (a): Response to danazol

Paulo Ricardo Criado, Danielle Priscilia De Souza Espineli, Neusayuriko Sakai Valentef, Afsaneh Alavi, Robert S. Kirsner

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Livedoid vasculopathy (LV) is a thrombo occlusive disorder presenting with recurrent painful ulcers of lower extremities. Association of LV with increased level of lipoprotein (a) (LP(a)), a risk factor for cardiovascular disease, has been reported. Danazol has been used with success in the management of LV, but none of the previous studies looked at the correlation between response to the treatment and level of LP(a). The aim of this study was to demonstrate the efficacy of low-dose danazol in the treatment of LV and its effects on LP(a). We present four cases with LV who were successfully treated with low-dose danazol, assessing the clinical characteristics and laboratory tests including the level of LP(a). The average age of the patients was 45 years and the mean duration of the disease was 19 years. The treatment regime of danazol 200 mg daily led to complete healing of ulcers and reduction in pain and a 70% (ranging from 52 to 87%) reduction in the level of LP(a). The limitation of this study is "small sample size." In our patients with LV, low-dose danazol led to clinical improvement along with significant reduction in the level of LP(a).

Original languageEnglish (US)
Pages (from-to)248-253
Number of pages6
JournalDermatologic Therapy
Issue number4
StatePublished - Jul 1 2015


  • pharmacology
  • skin signs of systemic disease
  • therapy-systemic

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Livedoid vasculopathy and high levels of lipoprotein (a): Response to danazol'. Together they form a unique fingerprint.

Cite this